# Novartis AG: Form 20-F for the period ended Dec 31, 2023

- Company: [Novartis AG](/companies/nvs.md) (CIK 1114448)
- Form: 20-F
- Filed: 2024-01-31
- Accepted by EDGAR: Jan 31, 2024, 07:38 ET
- Period: 2023-12-31
- Accession: 0001370368-24-000004
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114448/000137036824000004/nvs-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114448/000137036824000004/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | $12.47bn | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2023-01-01 to 2023-12-31 | $34.19bn | ifrs-full:GrossProfit |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | $9.77bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $551.0m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | $14.85bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | $7.10 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | $7.15 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | $14.46bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $1.06bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2023-12-31 | $13.39bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2023-12-31 | $30.48bn | ifrs-full:CurrentAssets |
| Total assets | at 2023-12-31 | $99.94bn | ifrs-full:Assets |
| Current liabilities | at 2023-12-31 | $26.39bn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2023-12-31 | $53.20bn | ifrs-full:Liabilities |
| Shareholders' equity | at 2023-12-31 | $46.67bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | at 2023-12-31 | 2,044,033,986 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1114448/000137036824000004/nvs-20231231.htm

Filed Jan 31, 2024.
Source: SEC EDGAR, the filing index for accession 0001370368-24-000004. Last ingested by Listed: Nov 9, 2026, 17:53 ET. No prices; not investment advice.